Zobrazeno 1 - 10
of 43
pro vyhledávání: '"J H, Grosset"'
Publikováno v:
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 16(8)
The objective of this review is to report evidence about the efficacy and potential of currently licensed drugs and new molecules beyond pre-clinical development for improving the chemotherapy of tuberculosis (TB). Rifapentine, a rifamycin with low m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a4a226279d6471d7d4d14f21685b02d3
https://pubmed.ncbi.nlm.nih.gov/23131273
https://pubmed.ncbi.nlm.nih.gov/23131273
Autor:
J. H. Grosset, W. R. Bishai
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 16:1708-1709
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f14e42d1f57aa20bdd40667b65b6a016
https://doi.org/10.5588/ijtld.12.0616-2
https://doi.org/10.5588/ijtld.12.0616-2
Autor:
J H, Grosset
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 69
During the last 15 years, new drugs active against Mycobacterium leprae have been identified. All of them belong to the fluoroquinolone, cycline and macrolide drug families. In the mouse model and in humans, minocycline, ofloxacin, and clarithromycin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::428fe13bfc6060260ccf64831ab84fd6
https://pubmed.ncbi.nlm.nih.gov/11757174
https://pubmed.ncbi.nlm.nih.gov/11757174
Autor:
B, Ji, J H, Grosset
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 67
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6c84af719a356d68860ae5608a2a8908
https://pubmed.ncbi.nlm.nih.gov/10700937
https://pubmed.ncbi.nlm.nih.gov/10700937
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 65(2)
In 1995, a field trial was implemented in Senegal in order to evaluate the efficacy of a regimen based on the monthly supervised intake of rifampin 600 mg, ofloxacin 400 mg and minocycline 100 mg to treat leprosy. During the first year of the trial,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c1c2978e740623f53086704351b0125b
https://pubmed.ncbi.nlm.nih.gov/9251595
https://pubmed.ncbi.nlm.nih.gov/9251595
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 64
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4a33a33ef64e9485000800744060eb8d
https://pubmed.ncbi.nlm.nih.gov/9030133
https://pubmed.ncbi.nlm.nih.gov/9030133
Autor:
J H, Grosset
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 62(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::86143fa751720094630670dcdc7e6c60
https://pubmed.ncbi.nlm.nih.gov/8046266
https://pubmed.ncbi.nlm.nih.gov/8046266
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 62(1)
The anti-Mycobacterium leprae activities of single doses of rifampin (RMP), clarithromycin (CLARI), or minocycline (MINO) alone, and various combinations of CLARI + MINO were determined in immunocompetent mice by the kinetic method. A single dose of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::134366507f2954979ff9e4d474f07773
https://pubmed.ncbi.nlm.nih.gov/8189087
https://pubmed.ncbi.nlm.nih.gov/8189087
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 60(4)
The bactericidal activities against Mycobacterium leprae of single or multiple doses of various combinations of new antileprosy drugs [minocycline (MINO), clarithromycin (CLARI), ofloxacin (OFLO), and sparfloxacin (SPFX)] and/or rifampin (RMP) were t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c7cedd849df236c973061861e4192348
https://pubmed.ncbi.nlm.nih.gov/1338596
https://pubmed.ncbi.nlm.nih.gov/1338596
Autor:
M, Constant-Desportes, C C, Guelpa-Lauras, J C, Carolina, A, Léoture, J H, Grosset, H, Sansarricq
Publikováno v:
International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association. 59(2)
A male born in 1930 was diagnosed as smear-positive borderline leprosy in 1971, and was treated with dapsone and/or sulfamethoxypyridazine from 1972 to 1980 with clinical improvement. However, new skin lesions with smears strongly positive appeared i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c2e8770e76f0cd0cc7491c04f8aea4c1
https://pubmed.ncbi.nlm.nih.gov/2071981
https://pubmed.ncbi.nlm.nih.gov/2071981